RECRUITING

Narrow Band Imaging for Gastric Neoplasia

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

It is thought that the development of cancer of the stomach follows a series of stages in which the lining becomes increasingly abnormal. Early detection of precursors of gastric cancer likely enable less invasive treatment. The assessment of gastric mucosa using the endoscope is used to detect cancers and these precursor lesions. Narrow band imaging uses filtered light already built into modern endoscopoes to identify the early changes in the gastric lining. The investigators' hypothesis is that narrow band imaging improves detection of precursor lesions and is a method amenable to international standardization. The investigators will conduct a prospective trial in which standard random biopsy, white light guided biopsy, and narrow band imaging guided biopsy will be performed for each patient. The yield of the different methods for gastric cancer precursors will thus be compared.

Official Title

Prospective Controlled Trial of Narrow Band Imaging for Detection of Gastric Cancer Precursors

Quick Facts

Study Start:2014-07
Study Completion:2023-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT02197351

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * presenting for upper endoscopy for gastric indications
  2. * gastric indications include upper abdominal pain dyspepsia abnormal gastric imaging iron deficiency anemia gastric ulcer management of GI blood loss without active bleeding reflux weight loss.
  1. * Subjects who are incarcerated, younger than 18, or unable to give informed consent will be excluded.
  2. * Patients who have evidence of active gastrointestinal bleeding will be excluded
  3. * Patients taking anti-thrombotic agents including clopidogrel, ticlopidine, coumadin, heparin, enoxaparin, and direct II or Xa inhibitors
  4. * Patients with INR \>1.5, platelet count \<75,000

Contacts and Locations

Study Contact

James Buxabum, MD
CONTACT
323 409 5371
jbuxbaum@usc.edu
Maria Trujillo
CONTACT
323 409 0939
mit@usc.edu

Principal Investigator

James Buxbaum, MD
PRINCIPAL_INVESTIGATOR
University of Southern California

Study Locations (Sites)

Los Angeles County Hospital
Los Angeles, California, 90033
United States

Collaborators and Investigators

Sponsor: University of Southern California

  • James Buxbaum, MD, PRINCIPAL_INVESTIGATOR, University of Southern California

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2014-07
Study Completion Date2023-12

Study Record Updates

Study Start Date2014-07
Study Completion Date2023-12

Terms related to this study

Keywords Provided by Researchers

  • stomach neoplasms
  • narrow band imaging
  • gastroscopy

Additional Relevant MeSH Terms

  • Gastric Cancer
  • Gastric Metaplasia
  • Gastric Dysplasia